The only difference we observed was a higher proportion of metastatic diagnosis among breast cancer patients treated with chemotherapy regimens with intermediate FN risk and not receiving prophylactic G-CSF compared to those receiving G-CSF. This evidence concerns the gene CSF3 and breast carcinoma.